While it has not yet received FDA approval for standard use, it has received orphan drug and fast track designations from the FDA to be used in TP53 positive MDS as of 16 April 2019, and breakthrough therapy designation as of 30 January 2020. This evidence concerns the gene TP53 and myelodysplastic syndrome.